News

Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology. "Immuno-oncology is a significant area of

The new research centre, which will include four integrated office/laboratory buildings of different heights, will house around 1900 workplaces and is scheduled to be completed between 2021 and

Under the deal, Zymeworks would receive the majority of $375m in potential rewards related to development and commercial milestones. The initial up-front payment, which Zymeworks will receive in

The trials met primary and key secondary endpoints, which included improvements in signs and symptoms of the disease versus placebo and associated improvements in physical function and quality

Certara will enhance its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform to assess the bioequivalence of drugs absorbed through the skin, while also factoring in variability in specific

The company is closely collaborating with the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as other key stakeholders, governments, and

The company will assess the safety, tolerability, and pharmacokinetics of TNX-201 in a healthy volunteers trial scheduled to be completed before the end of 2014. IMH has a

The double-blind, randomized, placebo-controlled LUME-COLON 1 trial will evaluate the efficacy and safety of nintedanib plus best supportive care (BSC), versus placebo plus BSC, after previous treatment with

While the current focus of the Company’s PolyStart technology is on TapImmune’s cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this